An infant boy, now 12 months of age, is evaluated in the pediatric clinic for a routine he… — USMLE Step 2 CK

An infant boy, now $12$ months of age, is evaluated in the pediatric clinic for a routine health maintenance visit. His past medical history is notable for a truncus arteriosus repair at age $4$ weeks. During his postoperative recovery, he developed tetany associated with a serum calcium level of $6.2 \text{ mg/dL}$ . Subsequent evaluation revealed an absent thymic shadow on a chest radiograph, and a confirmatory genetic test showed a microdeletion on chromosome $22\text{q}11.2$ . He has been taking oral calcium and vitamin D supplementation since discharge and has experienced no severe infections. His previous immunizations at $2$ , $4$ , and $6$ months of age consisted only of inactivated vaccines and were administered without complications. The parents are inquiring about the vaccines scheduled for today, which typically include measles-mumps-rubella (MMR), varicella, hepatitis A, and pneumococcal conjugate vaccines. Which of the following is the most appropriate action regarding his immunizations today?

A
Administer all typically scheduled vaccines, including MMR and varicella vaccines, to provide maximal protection.
B
Administer hepatitis A, pneumococcal conjugate, and MMR vaccines; withhold varicella vaccine due to the risk of disseminated viral infection.
Administer hepatitis A and pneumococcal conjugate vaccines; withhold MMR and varicella vaccines until T-lymphocyte function is confirmed to be adequate.Answer
D
Withhold all immunizations today and instead prescribe daily oral penicillin prophylaxis against encapsulated bacteria.
E
Administer all typically scheduled vaccines, but follow immediately with a $7$ -day course of acyclovir to prevent vaccine-strain viral replication.

Answer

The most appropriate action is to administer the inactivated vaccines (hepatitis A and pneumococcal conjugate) and withhold the live-attenuated vaccines (MMR and varicella) until the patient's T-lymphocyte function is evaluated.

Patients with DiGeorge syndrome (due to a

22\text{q}11.2

microdeletion) typically present with a triad of conotruncal cardiac anomalies, hypocalcemia secondary to parathyroid hypoplasia, and thymic hypoplasia or aplasia. The absence of a fully developed thymus leads to a variable degree of T-lymphocyte deficiency. Live-attenuated vaccines, such as the measles-mumps-rubella (MMR) and varicella vaccines, are contraindicated in patients with severe cellular immunodeficiencies because the vaccine-strain viruses can replicate unchecked and cause disseminated disease. Therefore, these live vaccines must be strictly withheld until a formal immunological evaluation (e.g., flow cytometry for CD3+ T-cell subsets and functional stimulation assays) confirms that the patient's cellular immunity is adequate. In contrast, inactivated vaccines, such as the hepatitis A and pneumococcal conjugate vaccines, cannot cause infection regardless of the patient's immune status and should be administered according to the normal schedule to provide necessary protection.

Step-by-Step Solution

Identify the patient's underlying genetic and immunological condition based on the clinical presentation.

The patient has DiGeorge syndrome (a

22\text{q}11.2

microdeletion), which is associated with thymic hypoplasia and potential T-cell deficiency.

Truncus arteriosus, neonatal hypocalcemia, and a

22\text{q}11.2

deletion form the classic diagnostic triad for DiGeorge syndrome.

Determine the implications of DiGeorge syndrome for childhood immunizations.

Patients with DiGeorge syndrome may have severe cellular (T-cell) immunodeficiency, making live-attenuated vaccines potentially dangerous.

Live viral vaccines can cause unchecked, disseminated infection in patients lacking adequate T-cell mediated immunity.

Classify the scheduled

12

-month vaccines as live-attenuated or inactivated.

MMR and varicella are live-attenuated vaccines; hepatitis A and pneumococcal conjugate are inactivated vaccines.

Understanding the fundamental composition of each vaccine dictates which can be safely administered.

Select the appropriate immunization management plan for this visit.

Administer the inactivated vaccines and defer the live-attenuated vaccines.

Inactivated vaccines pose no risk of disseminated infection and should be given on schedule. Live vaccines must be withheld until a CD3+ T-cell count and functional assays verify adequate cellular immunity.

Key Concept

Live-attenuated vaccines (e.g., MMR, varicella) are contraindicated in patients with severe cellular immunodeficiencies, such as DiGeorge syndrome, until adequate T-lymphocyte function is formally confirmed.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic